Imaging techniques valuable in glaucoma diagnosis

Article

Data from the ongoing European Optic Disc Assessment Trial (EODAT) indicated that imaging techniques could be valuable assets to ophthalmologists in the diagnosis of glaucoma, according to Nic Reus, MD, from the Glaucoma Service of The Rotterdam Eye Hospital, Rotterdam, The Netherlands.

Data from the ongoing European Optic Disc Assessment Trial (EODAT) indicated that imaging techniques could be valuable assets to ophthalmologists in the diagnosis of glaucoma, according to Nic Reus, MD, from the Glaucoma Service of The Rotterdam Eye Hospital, Rotterdam, The Netherlands.

"Glaucoma can be difficult to diagnose," Dr. Reus said. "The IOP may not be elevated in up to 50% of patients, and up to 50% of retinal ganglion cells may be lost early in the disease process."

The EODAT was designed to determine the accuracy and repeatability of European ophthalmologists in classifying stereoscopic optic disc photographs as healthy or glaucomatous and to compare their accuracy with that of GDxVCC (Carl Zeiss Meditec) and the Heidelberg Retina Tomograph (Heidelberg Engineering).

Stereoscopic optic disc photographs from 48 patients with glaucoma and 40 healthy individuals were evaluated. Sixteen photographs of healthy and glaucomatous eyes were duplicated for assessing intraobserver agreement, expressed as kappa. A total of 207 ophthalmologists classified the disc photographs as normal or glaucomatous.

Dr. Reus reported that the overall accuracy of the ophthalmologists in correctly classifying the photographs was 80.8%. In comparison, the GDxVCC, Heidelberg Retina Tomography, and Heidelberg Retina Tomography with Moorfields regression analysis correctly classified the photographs 93.2%, 89.8%, and 86.4%, respectively.

"Classification appears better by imaging than by most ophthalmologists. Classification is difficult for ophthalmologists," Dr. Reus concluded. "There were large variations among ophthalmologists and among countries. Imaging techniques appear to be better on average than ophthalmologists and these imaging techniques can be helpful to ophthalmologists in the diagnosis of glaucoma."

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.